Client News

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

Darwin AG to Present at Invest 2026 in Stuttgart and the Equity Forum in Frankfurt

CorTec Receives FDA Breakthrough Device Designation for Its Brain Interchange System in Stroke Rehabilitation — the First BCI Worldwide Designated for Stroke Motor Rehabilitation

Mallia Aesthetics Reports Positive Results from Consumer Study with its Hormone-Free 8T3 Essentials Lash & Brow Serum

Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead’s oncology pipeline.

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Proxygen Appoints Chiara Conti, Ph.D., as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation

AFYREN announces 2025 full-year financial results and the full takeover of its AFYREN NEOXY biorefinery

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting